Abstracts tagged "Arthritis"

Abstract Number: 2084 • 2015 ACR/ARHP Annual Meeting
Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Modulates Bone Resorption in Inflammatory Arthritis and Fracture Repair
Yahui Grace Chiu¹, Tzong-Ren Sheu², Jinbo Li³, Dongge Li⁴, Michael Thullen², Brendan Boyce⁵, Christopher T. Ritchlin⁶ and Javier Rangel-Moreno⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵University of Rochester, Rochester, NY, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁷Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Osteoclasts (OC) direct pathologic bone resorption in osteoporosis and inflammatory arthritis. We previously demonstrated that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a 7-pass transmembrane protein,…
Abstract Number: 1167 • 2015 ACR/ARHP Annual Meeting
Treating Experimental Arthritis with Adenoviral Overexpression of IL-22 or with Blocking Antibodies Against Endogenous IL-22 Both Reduces Inflammation and Destruction
Marije I. Koenders¹, Debbie M. Roeleveld¹, Loreto Parga¹, Shahla Abdolahi-Roodsaz¹, Fons A.J. van de Loo¹, Jay K. Kolls² and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Interleukin-22 (IL-22) is an IL-10 family cytokine member that was recently discovered to be mainly produced by Th17 cells. Previous studies have indicated the…
Abstract Number: 2090 • 2015 ACR/ARHP Annual Meeting
Gender-Specific Pathways Linking Arthritis, Activity Limitation and Incident Heart Disease: A Causal Mediation Analysis of the Canadian Longitudinal National Population Health Survey
Orit Schieir¹, Sheilah. Hogg-Johnson^1,2, Richard H Glazier^3,4,5,6 and Elizabeth M. Badley^1,7, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Institute for Work and Health, Toronto, ON, Canada, ³Family and Community Medicine, St. Michael's Hospital, Toronto, ON, Canada, ⁴Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, ON, Canada, ⁵Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁶Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁷Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Arthritis and activity limitation are risk factors for cardiovascular (CVD) morbidity and mortality. As arthritis is a major cause of activity limitation, the objective…
Abstract Number: 1206 • 2015 ACR/ARHP Annual Meeting
Presence of ACPA in a Large (>40.000) Population Based Cohort from the Netherlands
Elisabeth Brouwer¹, Suzanne Arends², Hendrika Bootsma¹, Caroline Roozendaal³, Pieter C Limburg⁴, Fiona Maas¹, René E. M. Toes⁵, T. W. J. Huizinga⁶, LA Trouw⁷ and Annemirthe Van Zanten¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁴Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) status provides important information regarding the diagnosis and prognosis of Rheumatoid Arthritis (RA). By using samples from blood bank donors…
Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Alexandra Steinberg¹, Harinder Chera¹, Yun-Jung Choi¹, Robert Martin¹, Charles McWherter¹, Yunbin Zhang², Pol Boudes¹ and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, ¹Cymabay Therapeutics, Newark, CA, ²INC Research, Raleigh, NC
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
Abstract Number: 1244 • 2015 ACR/ARHP Annual Meeting
Extracellular MicroRNAs in Synovial Fluid Reveal a Marked Proliferative Signature in Patients with Antibiotic-Refractory Lyme Arthritis
Robert B. Lochhead, Nancy D. Kim, Sheila Arvikar, Klemen Strle and Allen C. Steere, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA), caused by a tick-borne spirochete Borrelia burgdorferi, usually resolves appropriately with antibiotic treatment, called antibiotic-responsive LA. However, in some patients, arthritis…
Abstract Number: 2162 • 2015 ACR/ARHP Annual Meeting
Associations Between Education and Health Status Among Hispanics with Self-Reported Arthritis and/or Joint Pain
Leigha Vilen¹, Rebecca J. Cleveland², Alfredo Rivadeneira¹, Mary Altpeter³, Betsy Hackney⁴, Victoria Sepulveda² and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Institute on Aging, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC
Background/Purpose: Understanding the associations between education and health status among Hispanics with arthritis and/or joint pain is crucial in adapting existing arthritis interventions for this…
Abstract Number: 1345 • 2015 ACR/ARHP Annual Meeting
The Impact of Prior Antibiotic Treatment on Culture Results of Patients with Septic Arthritis
Ziv Paz¹, Sarah B. Lieber¹, Andrew Moore², Clara Zhu³, Mary Louise Fowler⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴School of Medicine, Boston University School of Medicine, Boston, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Synovial fluid culture and gram stain offer the most compelling proof of septic arthritis (SA); these tests are indicated in every suspected case. However,…
Abstract Number: 2259 • 2015 ACR/ARHP Annual Meeting
Incidence of Obesity, Diabetes and High Blood Pressure Associated with Arthritis: Analysis of the Canadian Longitudinal National Population Health Survey
Orit Schieir¹, Sheilah. Hogg-Johnson^1,2, Richard H Glazier^3,4,5,6 and Elizabeth M. Badley^1,7, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Institute for Work and Health, Toronto, ON, Canada, ³Family and Community Medicine, St. Michael's Hospital, Toronto, ON, Canada, ⁴Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, ON, Canada, ⁵Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁶Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁷Health Care & Outcomes Research, Toronto Western Res. Institute, Toronto, ON, Canada
Background/Purpose: While cross-sectional evidence points to a higher prevalence of cardiovascular (CVD) risk factors in persons with arthritis, longitudinal population based studies are lacking. The…
Abstract Number: 1346 • 2015 ACR/ARHP Annual Meeting
The Presentation and Outcomes of Surgically Treated Septic Arthritis: the Impact of Culture Results
Ziv Paz¹, Mary Louise Fowler², Clara Zhu³, Sarah B. Lieber¹, Andrew Moore⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²School of Medicine, Boston University School of Medicine, Boston, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Clinically-suspected septic arthritis is culture-negative in 18-43% of cases. These patients are often treated surgically with associated morbidity, prolonged hospital stays and high medical…
Abstract Number: 2283 • 2015 ACR/ARHP Annual Meeting
Current and Lifetime Smoking Among US Adults with Arthritis: A Serious Clinical and Public Health Issue
Louise Murphy¹, Miriam G. Cisternas² and Teresa J. Brady¹, ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²MGC Data Services, Carlsbad, CA
Background/Purpose: Smoking's adverse effects include increased risk of joint replacement failure and decreased medication effectiveness (e.g., methotrexate, TNF blockers). Because little is known about the…
Abstract Number: 1347 • 2015 ACR/ARHP Annual Meeting
The Presentations and Outcomes of Prosthetic Joint Septic Arthritis: a Comparison of Culture-Positive and Culture-Negative Disease
Ziv Paz¹, Sarah B. Lieber¹, Andrew Moore², Clara Zhu³, Robert H. Shmerling⁴ and Mary Louise Fowler⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴Medicine, Beth Israel Deaconess Medical Center, Boston, MA, ⁵School of Medicine, Boston University School of Medicine, Boston, MA
Background/Purpose: Prosthetic joint septic arthritis (PJSA) may complicate joint replacement in approximately 1-2% of cases. Synovial fluid cultures are negative in up to 25% of…
Abstract Number: 2372 • 2015 ACR/ARHP Annual Meeting
Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study
Alberto Sifuentes Giraldo¹, Carlo Alberto Scirè², Santos Castañeda³, Laura Nuño⁴, Francisco Javier Lopez Longo⁵, Julia Martínez-Barrio⁵, Franco Franceschini⁶, Ilaria Cavazzana⁶, Paolo Airò⁷, Elena Bartoloni Bocci⁸, Javier Bachiller Corral⁹, Rossella Neri¹⁰, Simone Barsotti¹¹, Roberto Caporali¹², Carlomaurizio Montecucco¹³, Marcello Govoni¹⁴, Renato La Corte¹⁴, Federica Furini¹⁴, Florenzo Iannone¹⁵, Margherita Giannini¹⁶, Enrico Fusaro¹⁷, Simone Parisi¹⁸, Giuseppe Paolazzi¹⁹, Giovanni Barausse¹⁹, Raffaele Pellerito²⁰, Alessandra Russo²⁰, Lesley Ann Saketkoo²¹, Norberto Ortego-Centeno²², Luca Quartuccio²³, Christof Specker²⁴, Andreas Schwarting²⁵, Kostantinos Triantafyllias²⁶, Carlo Selmi²⁷, Fausto Salaffi²⁸, Marco Amedeo Cimmino²⁹, Annamaria Iuliano³⁰, Fabrizio Conti³¹, Gianluigi Baiocchi³², Elena Bravi³³, Veronica Codullo¹², Anna Ghirardello³⁴, Trinitario Pina³⁵, Miguel Angel Gonzalez-Gay³⁵, Lorenzo Cavagna¹³ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ²Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁸Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹³Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁶DIM, Rheumatology Unit, Bari, Italy, ¹⁷Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁸Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ¹⁹Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²⁰Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²²Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ²³Clinic of Rheumatology, Department of Medical and Biological Sciences (DSMB), Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ²⁴Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁶ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ²⁸Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ²⁹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³⁰Osp. San Camillo, Roma, Italy, ³¹Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³²Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³³Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁴Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) are reported in up to 90% of patients affected by antisynthetase syndrome (ASSD) and thus represent the…
Abstract Number: 2050 • 2014 ACR/ARHP Annual Meeting
Knee Arthritis Is Positively Associated with Physical Impairment: Conclusion Based on Physical Examinations from a Cross-Sectional Study of 17708 Chinese Residents
Qiang Liu¹, Xu Tang Sr.², Xu Wu³, Zhengming Cao² and Jianhao Lin², ¹Arthritis Clinical and Reserch Center, Peking University People's Hospital, Peking University Health Science Center, Beijing, China, ²Peking University Health Science Center, Beijing, China, ³Peking University People's Hospital Arthritis Clinic & Research Center, Peking University Health Science Center, Beijing, China
Background/Purpose The prevalence of knee arthritis is high in both urban and rural China. Although the association between knee arthritis and limitation of daily activity…
Abstract Number: 67 • 2014 ACR/ARHP Annual Meeting
Effects of Exercise on Depressive Symptoms in Adults with Arthritis: A Systematic Review with Meta-Analysis
George A. Kelley¹, Kristi S. Kelley¹ and Jennifer Hootman², ¹Biostatistics, West Virginia University, Morgantown, WV, ²Population Health, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Previous randomized controlled trials have led to conflicting findings regarding the effects of exercise on depressive symptoms in adults with arthritis and other rheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.